Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries

Desjobert, Edouard; Tea, Victoria; Schiele, François; Ferrières, Jean; Simon, Tabassome; Danchin, Nicolás; Puymirat, Étienne

doi:10.1016/j.acvd.2020.06.003

Cited by 7 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason may be that the enhanced dual antiplatelet therapy (DAPT) after PCI in acute STEMI patients has a stronger inhibitory effect on platelet aggregation and effectively prevents recurrent myocardial infarction 27 . At the same time, the application of intensive lipid-lowering therapy 28 , β-receptor blockers, angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor antagonists (ARBs) also significantly reduced the incidence of angina and recurring myocardial infarction after STEMI 29 . We also consider that although MIRI is an important cause of death in STEMI patients, it also reflects the viable myocardium.…”

Section: Discussionmentioning

confidence: 99%

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

To establish a simple myocardial ischemia‒reperfusion injury (MIRI) manifestation grading system based on clinical manifestations and coronary angiography during primary percutaneous coronary intervention (PPCI). All STEMI patients treated with PPCI from June 2018 to November 2019 were included. According to the MIRI manifestation grade, patients were divided into four grades (I–IV). Laboratory and clinical indicators of the patients and the occurrence of major adverse cardiac events (MACEs) within one year of follow-up were analyzed. A total of 300 patients were included. The higher the MIRI manifestation grade, the lower was the high-density lipoprotein cholesterol (HDL-C); the higher were the C-reactive protein (CRP), lipoprotein(a) [LP(a)], and peak levels of high-sensitivity troponin T (hs-cTnT), creatine kinase (CK-MB), and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and the higher were the proportions of right coronary artery (RCA) and multivessel lesions (P < 0.05). The left ventricular end-diastolic dimension (LVEDD) and E/e′ values of patients with higher grades were significantly increased, while the LVEF, left ventricular short-axis functional shortening (LVFS) and E/A values were significantly decreased (P < 0.05). The one-year cumulative incidence of major adverse cardiac events (MACEs) in patients with grade I–IV disease was 7.7% vs. 26.9% vs. 48.4% vs. 93.3%, respectively, P < 0.05. The higher the MIRI manifestation grade, the more obvious is the impact on diastolic and systolic function and the higher is the cumulative incidence of MACEs within one year, especially in patients with multivessel disease, low HDL-C, high CRP, high LP(a) levels, and the RCA as the infarction-related artery.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Based on the one-way sensitivity analysis result, the long-term use of HIS among post-hospitalized ACS patients to prevent myocardial infarction and revascularization recurrence is preferable. Regardless of atherothrombotic risk classification, high-intensity statin medication at discharge after an acute myocardial infarction was linked with fewer major adverse cardiovascular events at five years, with the biggest absolute reduction reported in the high-risk TRS-2P class (Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention) [ 33 ]. This study result aligns with a few recent studies with retrospective database analyses, which showed the benefit of high-intensity statin use for secondary prevention of cardiac arrest, recurrent MI, and the need for revascularization [ 27 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Dewi,

Thavorncharoensap,

Rahajeng

2024

Egypt Heart J

View full text Add to dashboard Cite

Background Post-hospitalized acute coronary syndrome (ACS) patients in Indonesia National Insurance does not pay for the use of high-intensity statin (HIS) for secondary prevention after ACS hospitalization. Moreover, a cost–utility analysis needs to be conducted to evaluate the cost-effectiveness of prescribing HIS and low-to-moderate-intensity statin (LMIS) per quality-adjusted life year (QALY). This study aimed to estimate the cost–utility of long-term HIS treatment in post-hospitalized ACS patients in Indonesia compared to current practice. Results This study compared the economic outcomes of long-term HIS and LMIS in Indonesian post-hospitalized ACS patients. A lifetime Markov model predicted ACS-related events, costs, and QALY from a payer perspective. A systematic review estimated treatment-specific event probabilities, post-event survival, health-related quality of life, and Indonesia medical-care expenses from published sources. This study conducted probabilistic sensitivity analysis (PSA) using 1000 independent Monte Carlo simulations and a series of one-way deterministic sensitivity analyses utilizing a tornado diagram. The economic evaluation model proved that intensive HIS treatment can increase per-patient QALYs and care expenditures compared to LMIS. The use of HIS among post-hospitalized ACS patients had ICER 31.843.492 IDR per QALY gained, below the Indonesia willingness-to-pay (WTP) for terminal disease and life-saving treatment. Conclusion From the Indonesia payer perspective, using HIS for post-hospitalized ACS patients in Indonesia is cost-effective at 31.843.492 IDR per QALY gained.

show abstract

“…Desjobert et al evaluated the relationship between prescription of highintensity statin therapy at discharge and long-term clinical outcomes according to risk level defined by the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) after acute MI. 13 High-intensity statin therapy was associated with a non-significant decrease in domized trial; (2) high-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a numerically lower risk for cardiovascular events irrespective of the CREDO-Kyoto thrombotic risk in patients with CCS.…”

Section: Clinical Outcomes In the High-risk Intermediate-risk And Low...mentioning

confidence: 98%

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease　― Insights From the REAL-CAD Study ―

Natsuaki

Morimoto

Iimuro

et al. 2022

Circ J

View full text Add to dashboard Cite

intensity or maximal statin therapy are recommended in very high-risk atherosclerotic cardiovascular disease (ASCVD) patients. 3 Furthermore, a more intensive reduction of lowdensity lipoprotein cholesterol (LDL-C) in patients with ASCVD is recommended in the 2019 European Cardiology H igh-intensity statin therapy has been reported to be associated with significantly lower risk for cardiovascular events in patients with coronary artery disease. 1,2 In the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline, high

show abstract

Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries

Cited by 7 publications

References 17 publications

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease　― Insights From the REAL-CAD Study ―

Contact Info

Product

Resources

About

Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries

Cited by 7 publications

References 17 publications

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Novel grading system for ischemia‒reperfusion injury manifestations in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study ―

Contact Info

Product

Resources

About

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease　― Insights From the REAL-CAD Study ―